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Abstract
Background: Nowadays, when the majority of patients with acute myocardial infarction 
(AMI) are treated with primary percutaneous coronary intervention and modern pharmaco-
therapy, risk stratification becomes a challenge. Simple and easily accessible parameters that 
would help in a better determination of prognosis are needed. The aim of the study was to es-
timate the prevalence of high mean corpuscular volume (MCV, defined as MCV > 92 fL) and 
to establish its prognostic value in non-anemic patients with AMI.
Methods: We retrospectively analyzed the data of 248 consecutive non-anemic patients hospi-
talized due to AMI (median age: 65 [59–76] years, men: 63%, ST segment elevation myocar-
dial infarction: 31%, and median left ventricular ejection fraction [LVEF]: 50%).
Results: The prevalence of high MCV was 39 ± 6% (± 95% confidence interval) in the entire 
AMI population. High MCV was more prevalent in males, patients with low body mass index, 
non-diabetics and cigarette smokers (all p < 0.05). During the 180-day follow-up, there were 
38 (15%) events, defined as another AMI or death. In a multivariable Cox proportional hazard 
model, female gender (p < 0.01), low LVEF (p < 0.001), previous AMI (p < 0.05), arterial 
hypertension (p < 0.05), and high MCV (p < 0.001) were prognosticators of pre-defined events.
Conclusions: In non-anemic patients with AMI, high MCV is an independent prognostic 
factor of poor outcome defined as another AMI or death. (Cardiol J 2015; 22, 4: 421–427)
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Introduction
The determination of prognosis in patients 
after acute myocardial infarction (AMI) has always 
been difficult. Nowadays, when the majority of 
these patients are treated with primary percuta-
neous coronary intervention (PCI) and modern 
pharmacotherapy, risk stratification has become 
even more challenging.
It is obvious that patients after AMI with ane-
mia have greater cardiovascular risk [1–6], whereas 
in patients without anemia at admission the risk 
stratification remains equivocal. Easy and cheap 
parameters that would help in a better determina-
tion of prognosis are needed.
It is worth to mention that a complete blood 
count routinely performed in every patient admit-
ted with AMI includes a simple parameter, namely 
a red cell mean corpuscular volume (MCV), which 
potentially could be helpful in risk stratification. 
High MCV (macrocytosis) is known to be elevated 
in various conditions, regardless of concomitant 
anemia [7]. Several studies have addressed associa-
tions between high MCV and increased mortality, 
independently of anemia, in different pathologies, 
such as chronic kidney disease [8], acute heart 
failure [9], and in patients after PCI [10]. To the 
best of our knowledge, a prognostic value of high 
MCV among patients admitted due to AMI has not 
yet been analyzed.
Therefore, we performed the study in order to 
estimate the prevalence of high MCV in non-ane-
mic patients admitted due to AMI and to establish 
its prognostic value.
Methods
Study population
The retrospective study was conducted among 
consecutive patients hospitalized due to AMI in 
Center for Heart Diseases, the 4th Military Hospi-
tal in Wroclaw, between May and November 2012. 
There were only two exclusion criteria for the pur-
poses of this study: (1) lack of the patient’s written 
informed consent to participate in the study, and 
(2) anemia on admission. The diagnosis of AMI 
was established according to the third universal 
definition of myocardial infarction introduced by 
the European Society of Cardiology [11]. The study 
protocol was approved by the local Ethics Commit-
tee, and all subjects gave written informed consent. 
The study was conducted in accordance with the 
Declaration of Helsinki.
Clinical and laboratory data
For the purposes of the following study, we 
analyzed the following variables in patients admit-
ted due to AMI:
 — demographic and anthropometric characteris-
tics: sex, age, body mass index (BMI);
 — characteristics of AMI: type of AMI — either 
ST segment elevation myocardial infarction 
(STEMI) or non-STEMI (NSTEMI), peak 
troponin level, primary effective coronary 
revascularization;
 — medical history and co-morbidities: history 
of previous AMI, stroke, transient ischemic 
attack, concomitant diabetes mellitus, arterial 
hypertension, nicotinism, alcohol consump-
tion;
 — left ventricular ejection fraction (LVEF) es-
timated visually with the use of echocardiog-
raphy during first 48–72 h of hospitalization;
 — standard laboratory parameters measured on 
admission: hemoglobin, estimated glomerular 
filtration rate (eGFR), gamma-glutamyl trans-
peptidase (GGTP), low density lipoprotein 
(LDL) cholesterol;
 — medications administered prior to AMI: angio-
tensin-converting enzyme inhibitors (ACE-I), 
angiotensin receptor blockers (ARB), anti-
platelet drugs, beta-blockers, metformin and 
statins;
 — medications administered during the hospi-
talization and continued as post-discharge 
recommendations (post-AMI): ACE-I, ARB, 
antiplatelet drugs, beta-blockers, metformin 
and statins;
 — MCV measured on admission.
Anemia was defined according to the World 
Health Organization criteria as hemoglobin < 12 g/dL 
and < 13 g/dL in women and men, respectively 
[12]. MCV was assessed with the use of Sysmex 
XT-4000i and Sysmex XS-1000i Hematology Ana-
lyzers (Sysmex Inc., Kobe, Japan) and calculated 
according to the formula: [HCT(%)/RBC (×106/ 
/µL)] × 10 [13]. High MCV was defined as 
MCV > 92 fL (the upper limit of reference ranges 
in our laboratory, which is also a commonly ac-
cepted cut-off for the diagnosis of macrocytosis) 
[14]. Renal function was assessed using eGFR, 
calculated from the Modification of Diet in Renal 
Disease equation [15].
Survival analysis
The follow-up period of event-free survivors 
was 180 days. The study endpoint was considered 
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another AMI or death. The follow-up information 
was complete in all cases and was obtained from 
medical records.
Statistical analyses
Hemoglobin, eGFR and LDL cholesterol (as 
continuous variables with a normal distribution) 
were expressed as means ± standard deviations. 
The intergroup differences were tested using the 
Student’s t-test. Age, BMI, peak troponin level, 
LVEF and GGTP (being continuous variables with 
a skewed distribution) were expressed as medians 
with lower and upper quartiles. The intergroup 
differences were tested using the Mann–Whitney 
U-test. For further analyses, these variables were 
log transformed (a natural logarithm — ln) in 
order to normalize their distribution. Categorical 
variables were expressed as numbers with per-
centages. The intergroup differences were tested 
using the c2 test.
Clinical determinants of high MCV were estab-
lished using univariate logistic regression models.
Univariate and multivariable Cox proportional 
hazard regression models were used to calculate 
the predictive value of high MCV and other clini-
cal prognosticators for AMI and death. The multi-
variable model included all variables that had been 
shown to be significant (p < 0.05) prognosticators 
of another AMI and death in univariate models.
Kaplan–Meier event-free survival curves were 
constructed to demonstrate the effect of high MCV 
on cumulative survival. Differences in event-free 
survival rates were examined using the log-rank test.
A value of p < 0.05 was considered statisti-
cally significant. All statistical analyses were 
performed using the Statistica 10 data analysis 
software system (StatSoft Inc., Tulsa, Oklahoma, 
United States).
Results
Baseline characteristics of non-anemic  
patients admitted due to AMI
After exclusion of 48 patients with anemia on 
admission, the study population consisted of 248 
patients (Table 1). The median age was 65 (59–76) 
years, 63% of patients were men, and NSTEMI was 
the most common type of AMI (69%). The mean 
hemoglobin level was 14.0 ± 1.3 g/dL. The mean 
MCV was 91.4 ± 5.0 fL.
Determinants of high MCV
MCV > 92 fL was diagnosed in 96 non-anemic 
patients admitted due to AMI, which corresponds 
to a prevalence of 39 ± 6% (± 95% confidence in-
terval [CI]). None of the studied subjects had MCV 
< 80 fL, MCV ≤ 86 fL was found in 37 subjects, 
MCV > 86 fL and ≤ 92 fL in 115, MCV > 92 fL and 
≤ 98 fL in 76 and MCV > 98 fL in 20.
Men, patients with low BMI, those without 
diabetes and cigarette smokers were character-
ized by greater prevalence of high MCV (Table 1). 
High MCV was not related to alcohol consumption 
(Table 1).
Survival analysis
The proportion of patients surviving the 180- 
-day follow-up free from another AMI or death was 
85% (95% CI 80–89%).
In univariate Cox proportional hazard regres-
sion models (Table 2), the following variables were 
related with the increased risk of another AMI or 
death: female gender, advanced age, low LVEF, 
previous AMI, arterial hypertension, high LDL 
cholesterol and high MCV (all p < 0.05).
Female gender, low LVEF, previous MI, arte-
rial hypertension and high MCV (all p < 0.05) 
remained significant predictors of another AMI or 
death in patients hospitalized due to AMI also in 
the multivariable model (Table 2).
The 180-day event-free survival rates were 
76% (95% CI 68–85%) vs. 90% (95% CI 85–95%) in 
non-anemic patients admitted with AMI with high 
vs. normal MCV (c2 = 9.56, p = 0.002) (Fig. 1). 
The 180-day free of death survival rates were 
86% (95% CI 78–93%) vs. 95% (95% CI 91–98%) 
in patients with high vs. normal MCV (c2 = 5.50, 
p = 0.02). The difference in 180-day event-free 
survival rates 86% (95% CI 75–97%) vs. 91% (95% 
CI 86–96%) in patients with MCV ≤ 86 fL vs. MCV 
> 86 fL and ≤ 92 fL, respectively, was not significant 
(c2 = 0.64, p= 0.41). Neither was the difference 
75% (95% CI 65–85%) vs. 80% (95% CI 62–98%) 
in patients with MCV > 92 fL and ≤ 98 fL vs. 
MCV > 98 fL (c2 = 0.16, p = 0.69), respectively.
Discussion
Our study for the first time provides evidence 
on links between elevated MCV and cardiovascular 
risk in patients admitted due to AMI. Increased 
MCV (> 92 fL) has been associated with a higher 
incidence of subsequent cardiovascular event or 
death in these patients during a relatively short 
follow-up. Most importantly, this relationship has 
been demonstrated in non-anemic subjects.
MCV is one of standard blood morphology 
parameters assessed routinely, however, surpris-
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ingly receiving not much attention. Macrocytosis is 
defined as an enlargement of erythrocyte volume, 
commonly identified as an increase in MCV above 
100 fL [16]. However, some studies have demon-
strated that lesser deviations in the erythrocyte 
volume may also indicate pathology  and lower 
cut-off values for high MCV are also used (92 fL) 
[14, 17].
Changes in MCV reflect aberrations on vari-
ous steps of erythrocyte’s life cycle. Depending 
on the etiology of macrocytosis in non-anemic 
patients, we may distinguish its megaloblastic 
and non-megaloblastic forms [16]. Megaloblastic 
process is caused by impaired DNA synthesis that 
may be linked to certain drug administration (e.g. 
metformin, methotrexate, trimethoprim, nitrous 
oxide), folate or vitamin B12 deficiency [18, 19], 
for instance due to their insufficient supply in 
food [20, 21]. Non-megaloblastic macrocytes oc-
cur when a damaging factor acts after a completed 
erythropoiesis. Then, it can be caused e.g. by an 
increased deposition of lipids on the cell mem-
branes in the course of hepatobiliary diseases [19]. 
Other causes of non-megaloblastic macrocytosis in 
patients without anemia could be alcoholism [22] 
or familial macrocytosis [19]. The identification of 
high MCV does not allow to distinguish these two 
types of macrocytosis, and we need to acknowledge 
that the causes of high MCV found in almost 40% 
of non-anemic patients admitted due to AMI have 
not been investigated in our study, which might be 
considered as a study limitation.
The important and intriguing question is 
which pathophysiological processes are responsible 
for the demonstrated relationship between high 
MCV and increased cardiovascular risk in subjects 
without concomitant anemia. Our study was not 
designed to investigate these pathomechanisms, 
however some other studies may provide some 
potential explanations. Possible pathomechanisms 
can be more or less direct. A direct mechanism 
would be associated with a hindered flow of larger, 
less flexible erythrocytes through microcirculation, 
which is a phenomenon that might contribute to 
myocardial ischemia [23, 24]. Patients with high 
MCV commonly develop hyperhomocysteinemia 
[25], which is known to augment cardiovascular 
risk [26–28]. Moreover, high MCV is an independ-
ent prognosticator of impaired endothelial func-
tion measured via flow-mediated dilatation [8], 
which may be explained by disrupted erythrocyte 
antioxidative potential in macrocytes and an as-
sociated imbalance in global redox homeostasis of 
the organism [8]. Finally, macrocytosis may reflect 
a malnutrition, as associations between high MCV, 
and lower LDL cholesterol levels and lower BMI 
were reported [9, 10].
Conclusions
In summary, high MCV contributes to cardio-
vascular risk stratification in non-anemic patients 
with AMI. After verification of our observations 
in bigger cohorts and in other clinical contexts, 
commonly used scales for cardiovascular risk as-
sessment might potentially consider to include 
MCV to improve the preciseness of risk estimation, 
which seems to be easily attainable and probably 
economically advantageous.
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